CBUS — Cibus, Inc.

Cibus Q3 2025 Earnings Call Summary

1. Key Financial Results and Metrics

• Cash Position: As of September 30, 2025, cash and cash equivalents stood at $23.9 million, sufficient to fund operations into early Q2 2026.
• Revenue: Q3 revenue was $615,000, down from $1.7 million in the same period last year, attributed to the timing of partner-funded program activities.
• Expenses:
  • R&D expenses decreased to $10.8 million from $13 million year-over-year due to cost-cutting initiatives.
  • SG&A expenses were reduced to $5.2 million from $7.7 million.
• Net Loss: The net loss for Q3 was $24.3 million, significantly improved from $201.5 million in Q3 2024, which included a large noncash goodwill impairment charge.
• Annual Cash Burn Target: The company aims to reduce annual net cash usage to approximately $30 million by 2026.

2. Strategic Updates and Business Highlights

• Commercialization Focus: Cibus is concentrating on weed management traits, particularly herbicide-tolerant rice (HT1 and HT3), with 7 customer agreements signed across the U.S. and Latin America, representing 5-7 million addressable acres and a potential $200 million in annual royalties.
• Biofragrance Program: Successful pre-commercial pilot runs for biofragrance products have been completed, with initial payments expected in Q4 2025.
• Regulatory Progress: Positive developments in regulatory environments in the EU, Ecuador, and India are anticipated to facilitate market access for gene-edited products.
• Operational Efficiency: Consolidation of facilities and workforce reductions have been implemented to streamline operations and improve financial health.

3. Forward Guidance and Outlook

• Revenue Growth: Initial revenues from biofragrance products are expected in 2026, with a long-term revenue potential of $20 million to $40 million.
• Commercial Launch Timeline: Rice traits are on track for initial commercial launch in Latin America in 2027, followed by the U.S. in 2028 and Asia by 2030.
• R&D Partnerships: The company is exploring opportunities for R&D collaborations beyond its current focus areas, with significant interest from potential partners.

4. Bad News, Challenges, or Points of Concern

• Revenue Decline: The significant drop in Q3 revenue compared to the previous year raises concerns about the timing of commercialization efforts.
• Regulatory Delays: Although progress is being made, the EU regulatory process has been slower than anticipated, which could impact market entry timelines.
• Cash Runway: While the current cash position is adequate for near-term operations, the need for additional financing options remains a concern.

5. Notable Q&A Insights

• R&D Opportunities: There is optimism about potential R&D collaborations in 2026, driven by regulatory tailwinds and increased interest from partners.
• Market Potential in India: The collaboration with AgVaya is seen as a critical step for accessing the Indian rice market, which has a substantial acreage and demand.
• Biofragrance Revenue Expectations: Initial revenues from biofragrance products are expected to be in the single-digit millions in 2026, with potential for significant growth thereafter.
• Competitive Landscape: The company emphasized that herbicide-tolerant traits are well understood in the industry, providing a strong foundation for rapid market adoption compared to other traits like Pod Shatter Reduction.

Overall, Cibus is positioned for potential growth with its focused commercialization strategy, but faces challenges in revenue generation and regulatory timelines.